Drug intelligence / Profile preview

LY2428757 + TT223

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Peptides
Administration: Subcutaneous

Overview

**LY2428757 + TT223** was an investigational co-administration regimen for **type 2 diabetes mellitus**. It paired LY2428757, a once-weekly pegylated glucagon-like peptide 1 receptor agonist, with TT223, a daily gastrin analogue intended to stimulate gastrin-responsive beta-cell biology. In a four-week randomized study, adding 2 mg or 3 mg daily TT223 to 14 mg weekly LY2428757 did not provide additional glycaemic benefit versus LY2428757 alone and was associated with more frequent nausea and vomiting. ([sci-hub.cat](https://sci-hub.cat/storage/zero/7661/0fa26a6aac32bf1bd350176025dbbf36/bokvist2019.pdf))

Other names: LY + TT223LY+TT223LY2428757 + TT-223TT223 + LY2428757

Targets

GLP1R (GLP-1R)CCK2R (Cholecystokinin 2 Receptor)

Beyond the preview

Go deeper on LY2428757 + TT223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2428757 + TT223.

Explore the full profile